Background--The 2013 American College of Cardiology/American Heart Association cholesterol guidelines recognize cardiovascular disease and diabetes mellitus but not chronic kidney disease (CKD) as high-risk conditions warranting statin therapy. Statin use may be lower for adults with CKD compared with adults with conditions that have guideline indications for statin use.
A number of studies over the past 15 years have demonstrated that adults with chronic kidney disease (CKD) have high cardiovascular disease (CVD) risk. [1] [2] [3] [4] For example, in an analysis of 3 community-based cohort studies, the incidence of coronary heart disease and stroke events was 24.5 and 13.4 per 1000 person-years, respectively, among those with CKD and 8.4 and 4.8 per 1000 personyears, respectively, among their counterparts without CKD. 5 High low-density lipoprotein-cholesterol (LDL-C) is a risk factor for CVD, both in the general population 6 and among adults with CKD. 7 Statins, which lower LDL-C, are a key therapy for preventing CVD 8, 9 and randomized controlled trials have demonstrated as much as a 25% risk reduction in atherosclerotic events and mortality with statin therapy in adults with CKD not requiring dialysis. [10] [11] [12] Statin use has increased markedly among US adults between 1999-2000 and 2011-2012. 13 Additionally, there has been increased awareness of the high CVD risk among adults with CKD. 14 Studies using data collected in the early 2000s reported that adults with CKD were less likely to be taking a statin compared with their counterparts without CKD. 15 In 2013, the American College of Cardiology/American Heart Association (ACC/AHA) updated the US guideline on the treatment of blood cholesterol and shifted to an atherosclerotic cardiovascular disease (ASCVD) risk-based approach to guide treatment. 9 While a history of CVD, diabetes mellitus, LDL-C ≥190 mg/dL, and 10-year predicted ASCVD risk ≥7.5% were indications for statin therapy, CKD was not included as a statin benefit group in this guideline. A population-based study of middle-aged and older adults recruited between 2003 and 2007 found that 92% of adults with CKD had an indication for a statin based on the 2013 ACC/AHA cholesterol guideline. 15 However, only 50% of participants were taking a statin. The 2018 ACC/AHA cholesterol guideline defined CKD as a risk-enhancing factor for the primary prevention of ASCVD and recommends statins for adults with non-dialysis-dependent CKD who have LDL-C ≥70 mg/dL and a 10-year ASCVD risk ≥7.5%. 16 It is unclear whether a difference in statin use still exists between adults with versus without CKD. Therefore, we examined trends in statin use from 1999-2002 through 2011-2014 among US adults with and without CKD. We additionally compared statin use among adults with CKD to those with diabetes mellitus, a specific indication for a statin based on the 2013 ACC/AHA cholesterol guideline. Finally, we examined trends in nonstatin lipid-lowering therapy (NSLLT) use among adults with and without CKD.
Methods
The data and study materials are publicly available. 17 The analytic methods have been made available within the article to other researchers for purposes of reproducing the results or replicating the procedure. The National Health and Nutrition Examination Survey (NHANES) is conducted in 2-year cycles by the National Center for Health Statistics of the Centers for Disease Control and Prevention. 18 Each 2-year cycle includes a sample of the non-institutionalized civilian US population identified through a stratified, multistage probability sampling design. Two-year cycles can be combined to produce more stable prevalence estimates. For the current analysis, we included adults who were ≥20 years of age (n=38 336) in the eight 2-year cycles conducted from 1999-2000 through [2013] [2014] 
Data Collection
Data were collected through questionnaires and a physical examination. Questionnaires were used to obtain information on age, race, sex, education, income, smoking, history of CVD, and antihypertensive and glucose-lowering medication use. During the physical examination, blood pressure, height, and weight were measured and blood and a random spot urine sample were collected. Body mass index was calculated using weight and height as measured during the study visit and categorized as <25, 25 to <30, and ≥30 kg/m 2 .
Blood pressure was measured 3 times following a standardized protocol and averaged for all analyses. Hypertension was defined as systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥90 mm Hg, or antihypertensive medication use. Glucose, glycated hemoglobin, creatinine, total and high-density lipoprotein-cholesterol (HDL-C), and triglycerides were measured using blood collected during the study visit. LDL-C was calculated using the Friedewald equation. 19 Non-HDL-C was calculated as total cholesterol minus HDL-cholesterol. Estimated glomerular filtration rate (eGFR) was calculated using serum creatinine and the Chronic Kidney Disease Epidemiology Collaboration equation. 20 Reduced eGFR was defined by levels <60 mL/min per 1.73 m 2 . 21 With the use of a random spot collection, urinary albumin and creatinine were measured and the albumin-to-creatinine ratio was calculated. Albuminuria was defined as an albumin-to-creatinine ratio ≥30 mg/g. CKD was defined as reduced eGFR or albuminuria. Use of statins and NSLLT medications were determined through a pill bottle review that was conducted as part of the study examination. During the household interview, survey participants were asked to show all prescription medications taken in the past 30 days. Statins included atorvastatin, simvastatin, rosuvastatin, fluvastatin, pitavastatin, lovastatin, and cerivastatin. NSLLT included fibric acid derivatives, bile acid sequestrants, cholesterol absorption inhibitors, and niacin. Medication doses were not available.
Clinical Perspective
What Is New?
• Approximately two thirds (65%) of adults with chronic kidney disease (CKD) were recommended a statin based on the 2013 American College of Cardiology/American Heart Association guideline; however, only 36% of adults with CKD were taking a statin in 2011-2014.
• The prevalence of statin use was lower among adults with CKD in the absence of another condition with high CVD risk (ie, diabetes mellitus) compared with adults with diabetes mellitus in the absence of CKD.
What Are the Clinical Implications?
• These data demonstrate the underutilization of statins among patients with CKD and this suggests that its use may increase with its recognition as a risk-enhancing factor in the 2018 American College of Cardiology/American Heart Association cholesterol management guideline.
CVD Risk Groups
There are 4 broad indications for statin therapy in the 2013 ACC/AHA guideline: history of CVD, diabetes mellitus, LDL-C ≥190 mg/dL, and 10-year predicted ASCVD risk ≥7.5% as defined by the Pooled Cohort risk equations. 9 In the current study, history of CVD was defined as a self-report of a prior diagnosis of myocardial infarction, coronary heart disease, or stroke. Diabetes mellitus was defined as a fasting plasma glucose ≥126 mg/dL, nonfasting glucose ≥200 mg/dL, glycated hemoglobin level ≥6.5%, or self-report of a history of diabetes mellitus with concurrent glucose-lowering medication use. Adults were categorized into 5 hierarchical and mutually exclusive CVD risk groups defined by the first of the following conditions met: (1) history of CVD, (2) diabetes mellitus, (3) LDL-C ≥190 mg/dL (non-HDL-C ≥220 mg/dL for nonfasting adults), (4) 10-year predicted ASCVD risk ≥7.5%, and (5) 10-year predicted ASCVD risk <7.5%. A small number of NHANES participants had LDL-C ≥190 mg/dL or non-HDL-C ≥220 mg/dL in the absence of CVD or diabetes mellitus (n<50 in each calendar period). Therefore, results from this group are not presented.
Statistical Analysis
NHANES cycles were pooled into 4-year calendar periods (1999-2002, 2003-2006, 2007-2010, 2011-2014) To contrast statin use for adults with CKD versus their counterparts with a specific indication for treatment, we calculated the percentage of US adults with CKD in the absence of diabetes mellitus and with diabetes mellitus in the absence of CKD who were taking a statin within each calendar period. This analysis was conducted among those with and without a history of CVD, separately. Poisson regression was used to calculate PRs for statin use in 2011-2014 comparing US adults with CKD in the absence of diabetes mellitus versus diabetes mellitus in the absence of CKD with 3 levels of adjustment as described above.
Finally, we calculated the percentage of US adults with and without CKD adults who were taking NSLLT overall, NSLLT monotherapy (ie, NSLLT without a statin), and combination statin/NSLLT therapy, separately. Using Poisson regression with 3 levels of adjustment as described above, we calculated PRs for NSLLT use comparing US adults with versus without CKD during the overall study period (1999-2014). All statistical tests were 2 sided with a P<0.05 considered statistically significant. NHANES sampling weights were used in all calculations to obtain US nationally representative prevalence estimates, and the complex sampling design of NHANES was taken into account in all analyses. Stata 13.1 (StataCorp, College Station, TX) was used for all analyses.
Results

Population Characteristics
In each calendar period, the majority of US adults with CKD were older than 60 years of age compared with fewer than 25% of their counterparts without CKD (Table 1) . Those with CKD were less likely to be male compared with their counterparts without CKD. Adults with CKD were more likely to have less than a high school education; have an annual household income <$20 000; be former smokers; and have a body mass index ≥30 kg/m 2 , hypertension, diabetes mellitus, and a history of CVD compared with those without CKD. Also, among those without a history of CVD, individuals with CKD were more likely to have a 10-year ASCVD risk ≥7.5%. In 2011-2014, 65.3% of adults with CKD versus 27.4% of adults without CKD had an indication for statins based on the 2013 ACC/AHA cholesterol guideline.
Statin Use Among Those With and Without CKD
Between 1999-2002 and 2011-2014, the percentage of US adults ≥20 years taking statins increased from 17.6% to 35.7% for those with CKD and from 6.8% to 14.7% for those without CKD. Among adults with and without CKD, statin use increased in each CVD risk group except for those who had CKD and a 10-year predicted ASCVD risk <7.5% ( Figure 1 and Table S1 ). In the overall population and within CVD risk groups, trends in the percentage of US adults taking statins between 1999-2002 and 2011-2014 were not statistically Table 2 ). The percentage of US adults taking statins was higher with progressively more severe CKD and for those with versus without albuminuria (Table S2 ). Statin use increased from 1999-2002 to 2011-2014 within each CKD stage and for participants with and without albuminuria. After multivariable adjustment, individuals with stage 3 CKD compared with no CKD were more likely to be taking a statin (Table S3) .
Having albuminuria was not associated with statin use after multivariable adjustment (Table S4) .
Statin Use Among Those With CKD and Diabetes Mellitus
Among adults without a history of CVD, statin use increased between 1999-2002 and 2011-2014 from 10.0% to 21.0% for those with CKD in the absence of diabetes mellitus and from 17.5% to 40.4% among their counterparts with diabetes mellitus in the absence of CKD ( Figure 2 and Table S5 ). 76.1% among their counterparts with diabetes mellitus in the absence of CKD. Among US adults without CVD, those with CKD in the absence of diabetes mellitus were less likely to be taking a statin compared with their counterparts with diabetes mellitus in the absence of CKD (multivariable-adjusted PR 0.54; 95% CI, 0.44-0.66; Table 3 ). Among US adults with a history of CVD, the PR for taking statins was 0.95 (95% CI, 0.79-1.15) comparing those with CKD in the absence of diabetes mellitus versus their counterparts with diabetes mellitus in the absence of CKD.
NSLLT Use
Between 1999-2002 and 2011-2014, the percentage of US adults taking NSLLT increased from 2.6% to 7.1% among those with CKD and from 1.1% to 2.1% among those without CKD (Table S6) . In unadjusted analyses, US adults with CKD were 3.26 times (95% CI, 2.77-3.83) more likely than their counterparts without CKD to be taking NSLLT (Table S7 ). This association was attenuated but remained statistically significant after multivariable adjustment (PR, 1.34; 95% CI, 1.12-1.59). Statin monotherapy and combination statin/NSLLT therapy increased, while there was no evidence of a change in the proportion taking NSLLT monotherapy among participants both with and without CKD (Table S8) .
Discussion
There are several key findings from the current study. In the general US population, statin use has increased over the past 2 decades. 13 Before 2013, statin use was recommended based on cholesterol levels in US guidelines. 23 The and Assessment of Lescol in Renal Transplantation trial reported a low incidence of statin-related side effects in adults with CKD, and these rates were similar for adults with and without CKD. 31, 32 In 2013, the ACC/AHA updated recommendations for the management of blood cholesterol and adopted an approach that uses ASCVD risk in conjunction with LDL-C to guide statin treatment. 9 The National Kidney Foundation's task force on CVD concluded in 1998 that the incidence of ASCVD was higher in adults with CKD compared with the general population and that CKD should be a risk equivalent for coronary heart disease. 33 However, the 2013 ACC/AHA cholesterol guideline writing committee did not include CKD as a condition warranting treatment with a statin. 9 In the current analysis of nationally representative data, almost two thirds of US adults with CKD had an indication for taking a statin but only 35.7% were taking one. More recently, the 2018 ACC/AHA cholesterol treatment guidelines considered CKD as a risk-enhancing factor for ASCVD. While it is unknown what impact the 2018 ACC/AHA guideline will have on the proportion of US adults with CKD taking statins, results from the current study highlight the underutilization of statins among adults with CKD.
Statins are effective in preventing cardiovascular events and delaying mortality in adults with mild and moderate CKD. In a meta-analysis of 26 34 While the current results demonstrate that statin use has increased over time, by 2011-2014 still only 35.7% of US adults with CKD were taking a statin. Although US adults with CKD were more likely than those without CKD to be taking an NSLLT, the absolute percentage of those with CKD taking NSLLT was low. Including CKD as an indication for statins may result in treatment uptake in this high-risk population. In the current study, we compared adults with CKD who lack a specific indication for a statin to adults with diabetes mellitus who have a specific indication for treatment. There was no difference in the proportion of US adults with CKD in the absence of diabetes mellitus versus with diabetes mellitus in the absence of CKD taking statins in the presence of CVD, which is an indication for statin therapy. However, among those without a history of CVD, US adults with CKD in the absence diabetes mellitus were less likely to be taking a statin when compared with those with diabetes mellitus in the absence of CKD. The lower rate of statin use in those with CKD versus diabetes mellitus may represent a missed treatment opportunity that could potentially be eliminated as the 2018 ACC/AHA cholesterol management includes CKD as a risk-enhancing factor for statin treatment. 16 There are several strengths to the current analysis. NHANES provides nationally representative estimates for noninstitutionalized US adults. Data were collected using standardized questionnaires, and procedures used were consistent over the 16-year study period. We acknowledge some limitations to the current analysis. Enrollment in NHANES was restricted to non-institutionalized US adults and did not include nursing home residents. NHANES participants are not followed, and we are unable to identify those who initiated a statin following their study visit. NHANES data on statin use are currently available only through 2014, only 1 year following the publication of the 2013 ACC/AHA cholesterol guideline. As there is often a delay in implementation of treatment guidelines, these data may not reflect the full impact of the 2013 ACC/AHA cholesterol guideline on the prevalence of statin use. Between 2009 and 2015, the proportion of patients in a large, integrated health system remained stable for those with ASCVD, high LDL-C, and diabetes mellitus but increased substantially for those with 10-year ASCVD risk ≥7.5%; there was no information on contemporary statin use in populations with CKD. 35 In older cohorts of CKD populations, however, statins are consistently underused. 15, 36, 37 In conclusion, statin use increased between 1999-2002 and 2011-2014 among US adults with and without CKD. Despite over 65% of adults with CKD being recommended a statin based on the 2013 ACC/AHA guideline, only 35.7% of adults with CKD were taking a statin in 2011-2014. Statin use was lower among adults with CKD in the absence of diabetes mellitus compared with those with diabetes mellitus in the absence of CKD. This difference highlights the importance of recognizing the high CVD risk in patients with CKD and potential benefits of increased statin utilization. Implementation of the 2018 ACC/AHA cholesterol guideline, which considers CKD a risk-enhancing factor, may increase the appropriate use of statins in this high-risk population.
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